Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PanACEA-MAMS-TB-01
PACTR201205000383208Phase 2Unknown
- Sponsor
- Prof. Karl Walter Jauch, Medical Director, Klinikum of the Universtiy of Munich
- Start
- Jan 2013
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 2 trial of rifampicin, SQ109, moxifloxacin, isoniazid, pyrazinamide and 1 more in Tuberculosis (TB) and pulmonary tuberculosis (TB) (5 arms), sponsored by Prof. Karl Walter Jauch, Medical Director, Klinikum of the Universtiy of Munich. Primary endpoint: Time to stable culture conversion to negative in liquid media. Status: unknown.
02
Drugs
rifampicinSQ109moxifloxacinisoniazidpyrazinamide
03
Conditions
Tuberculosis (TB)pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on PACTR201205000383208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR201205000383208.